EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte Studie

Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects

Inyoung Hwang iD, Sang Chun Ji, Jaeseong Oh, Hyojin Kim, Hyunju Cha, John Kim, Chang-Seok Lee, Kyung-Sang Yu iD, SeungHwan Lee iD

Alimentary Pharmacology & Therapeutics · 2023-04 · 57 (7) · 763-772

DOI: 10.1111/apt.17406 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, published online on 2023-02-02. Written by Inyoung Hwang and 8 co-authors. Institution: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Major MEDLINE topics: Potassium, Esomeprazole. Cited 28 times so far (Crossref); 31 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Zastaprazan (JP‐1366) is a novel potassium‐competitive acid blocker with favourable preclinical safety and efficacy profile being developed for the treatment of acid‐related diseases.

Aims

To investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan.

Methods

A randomised, open‐label, placebo‐ and active‐controlled, single and multiple ascending dose clinical trial was conducted in healthy Korean male subjects. Intragatric pH and serum gastrin were measured to assess the pharmacodynamics, while serial blood and urine samples were collected to assess the pharmacokinetics. Pharmacogenomic evaluation was conducted to explore genetic variants, which can affect the pharmacodynamics and pharmacokinetics. Safety and tolerability including hepatotoxicity were evaluated.

Results

Suppression of gastric acid secretion increased as the dose of zastaprazan increased. The percentage of time that gastric pH was over 4 (%Time pH >4) with zastaprazan 20 mg (85.19%) and 40 mg (91.84%) were similar to or greater than that with esomeprazole 40 mg (72.06%). Zastaprazan was rapidly absorbed within 2 h and eliminated with a half‐life of 6–10 h. Pharmacogenomic analysis found no genetic variant of drug metabolising enzymes including CYP2C19 or drug transporters associated with the exposure of zastaprazan. Zastaprazan was well tolerated with no clinically significant changes in safety and tolerability assessments.

Conclusions

Zastaprazan was safe and well tolerated after a single oral dose up to 60 mg and multiple oral doses up to 40 mg. It also showed rapid, potent suppression of gastric acid secretion. Pharmacodynamic and pharmacokinetic profile of zastaprazan was suitable for treatment of patients with acid‐related diseases.

Subjects

MeSH terms (MEDLINE)

PotassiumEsomeprazoleHumansMaleHealthy VolunteersDouble-Blind MethodGastrinsDose-Response Relationship, DrugAdministration, Oral

Substances

PotassiumEsomeprazoleGastrins

Authors and institutions

  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
  • Onconic Therapeutics Inc., Seoul, Republic of Korea.
  • Jeil Pharmaceutical CO., LTD., Seoul, Republic of Korea.

ORCID profiles: Inyoung Hwang, Kyung-Sang Yu, SeungHwan Lee

Cite

APA

Hwang, I., Ji, S. C., Oh, J., Kim, H., Cha, H., Kim, J., Lee, C. S., Yu, K. S., & Lee, S. (2023). Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects. Alimentary Pharmacology & Therapeutics, 57(7), 763-772. https://doi.org/10.1111/apt.17406

Vancouver

Hwang I, Ji SC, Oh J, Kim H, Cha H, Kim J, et al. Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects. Alimentary Pharmacology & Therapeutics. 2023;57(7):763-772. doi:10.1111/apt.17406

BibTeX
@article{Hwang2023,
  author = {Hwang, Inyoung and Ji, Sang Chun and Oh, Jaeseong and Kim, Hyojin and Cha, Hyunju and Kim, John and Lee, Chang-Seok and Yu, Kyung-Sang and Lee, SeungHwan},
  title = {Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {7},
  pages = {763--772},
  doi = {10.1111/apt.17406}
}
Start for free →